Myovant Sciences Revenue 2017-2021 | MYOV

Myovant Sciences revenue from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Myovant Sciences Annual Revenue
(Millions of US $)
2021 $59
2020 $
2019 $
2018 $
2017 $
2016 $
Myovant Sciences Quarterly Revenue
(Millions of US $)
2021-09-30 $78
2021-06-30 $41
2021-03-31 $25
2020-12-31 $1
2020-09-30
2020-06-30 $33
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.260B $0.059B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81